Abstract

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis. Indonesia ranks third in the number of global TB cases. Studies in Indonesia show reduced levels of Hb, Ht, MCV, MCH, and leukocytosis in newly diagnosed and untreated TB patients, with 60% having anemia. The combined use of hematologic markers to assess inflammatory response before and after treatment still needs further investigation.This study was conducted in several Puskesmas in Semarang to determine the hematological profile of tuberculosis patients before and after 1 month of treatment. This study used a quasi-experimental design with one-group pre-test and post-test methods. The study population included all TB patients in the third area of the Puskesmas. Non-probability sampling technique with quota sampling is used to select a sample, consisting of newly diagnosed TB patients (aged 20-60 years, both male and female, and not cases of retreatment). A total of 30 samples were taken (10 from each Puskesmas). Analysis of blood samples is performed using the automated hematology device Sysmex (KX21-N). Data were analyzed using SPSS Version 25 with descriptive statistics and paired t-test was used to compare hematologic profiles before and after treatment. The results showed that anemia often occurred in tuberculosis patients and the number of patients who experienced anemia after treatment decreased from 16 patients to 13 patients. The study also found significant changes in white blood cell (p = 0.004) and platelet (p = 0.005) counts in tuberculosis patients before and after treatment. The increase in white blood cell count after treatment shows clinical improvement, while the decrease in platelets may be due to the action of anti-tuberculosis drugs. Normocytic normochromic anemia is the most common form of anemia in tuberculosis patients before treatment, while microcytic hypochromic anemia is more common after 1 month of treatment.

There is no Figure or data content available for this article

References

• 1. Isbaniah F, Burhan E, Sinaga BY, et al. Tuberkulosis Pedoman Diagnosis Dan Penatalaksanaan Di Indonesia. Vol 001. Revisi 2. Perhimpunan Dokter Paru Indonesia; 2021. https://klikpdpi.com/bukupdpi/wp-content/uploads/2022/08/BUKU-GUIDELINE-TB-2021.pdf
• 2. World Health Organization. Global Tuberculosis Report 2022.; 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports
• 3. World Health Organization. Global Tuberkulosis Report 2021.; 2021. https://www.who.int/publications/i/item/9789240037021
• 4. Kementerian Kesehatan RI. Profil Kesehatan Indonesia. Kemenkes RI; 2021.
• 5. Dinkes Kota Semarang 2021. Profil Kesehatan Kota Semarang 2021.; 2021. https://dinkes.semarangkota.go.id/content/menu/7
• 6. Kassa E, Enawgaw B, Gelaw A, Gelaw B. Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematol. 2016;16(1):2-11. doi:10.1186/s12878-015-0037-1
• 7. Bonsome B. Evaluation of Haematological Parameters in the Initial Phase of Anti-Tuberculosis Therapy in Yenagoa, Nigeria. Niger Delta Med J. 2017;1(4):10-15. http://ndmjournal.org/wp-content/uploads/2018/03/Evaluation-of-haematological-parameters-in-the-initial-phase.pdf
• 8. ?tefanescu S, Coco? R, Turcu-Stiolica A, et al. Evaluation of Prognostic Significance of Hematological Profiles after the Intensive Phase Treatment in Pulmonary Tuberculosis Patients from Romania. PLoS One. 2021;16(4 April):1-18. doi:10.1371/journal.pone.0249301
• 9. Naranbhai V, Hill AVS, Abdool Karim SS, et al. Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at risk of Incident Tuberculosis among HIV-Infected Adults Initiating Antiretroviral Therapy. J Infect Dis. 2014;209(4):500-509. doi:10.1093/infdis/jit494
• 10. Fayed HM, Mohammed AE, Badawy MS, Yassin AS. The Utility and Validity of Immunological, Inflammatory, and Nutritional-based Scores and Indices in Active Pulmonary Tuberculosis. Int Clin Pathol J. 2018;6(6):199-213. doi:10.15406/icpjl.2018.06.00188
• 11. Gunluoglu G, Yazar EE, Veske NS, Seyhan EC, Altin S. Mean Platelet Volume as an Inflammation Marker in Active Pulmonary Tuberculosis. Multidiscip Respir Med. 2014;9(1):1-5. doi:10.1186/2049-6958-9-11
• 12. Yuniza F, Nuraini S, Putra Danan Jaya B, et al. Profil Hematologi Pasien Tuberkulosis Paru Di Kota Bandar Lampung. J Media Kesehat. 2022;12(2):154-163. doi:https://doi.org/10.33088/jmk.v15i2.864
• 13. Asa Qurrotul’ Ain, Sayekti S, Dwi Prasetyaningati. Gabaran Indek Eritrosit Pada Penderita Tuberkulosis (TBC) Paru Pada Usia 15-55 Tahun. J Insa Cendekia. 2019;7(1):8-12.
• 14. Corporation S. Operator’s Manual Sysmex KX-21.; 2014. https://5.imimg.com/data5/OF/YZ/FH/SELLER-4426370/sysmax-kx-21.pdf
• 15. Bain BJ, Bates I, Laffan MA, Lewis SM. Dacie and Lewis Practical Haematology. Eleventh. Elsevier Ltd; 2012.
• 16. Saxena R, Chamoli S, Batra M. Clinical Evaluation of Different Types of Anemia. World J Anemia. 2018;2(1):26-30. doi:10.5005/jp-journals-10065-0024
• 17. Hamid GA. Clinical Hematology.; 2014. https://www.researchgate.net/publication/260266684
• 18. Abaker M, Mohammed S, Abaker M, Mohammed S. Some Hematological Parameters among Patients with Pulmonary Tuberculosis – Khartoum State. Sch J Appl Med Sci. 2016;4(2347-954):99-111. doi:10.36347/sjams.2016.v04i01.020
• 19. Javed I, Javed MT, Mahmood Z, Riaz M, Iqbal R, Rasul A. Hematological profiling of tuberculosis-infected and co-morbid patients: A study carried out in central Punjab, Pakistan. Eur J Inflamm. 2018;16. doi:10.1177/2058739218818684
• 20. Shah AR, Desai KN, Maru AM. Evaluation of Hematological Parameters in Pulmonary Tuberculosis Patients. J Fam Med Prim Care. 2022;11(8):4424-4428. doi:10.4103/jfmpc.jfmpc_2451_21
• 21. Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2022.; 2023. https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
• 22. Situmorang PR. Kadar Hemoglobin Penderita Tuberkulosis Paru Yang Menjalankan Terapi Obat Anti Tuberkulosis Di Puskesmas Pancur Batu Kabupaten Deli Serdang 2019. Elisabeth Heal J. 2020;5(02):72-79. doi:10.52317/ehj.v5i02.313
• 23. Kementerian Kesehatan RI. Rokok & TBC.; 2022. https://p2ptm.kemkes.go.id/kegiatan-p2ptm/dki-jakarta/rokok-tbc-pengendalian-konsumsi-rokok-adalah-salah-satu-strategi-eliminasi-tuberkulosis
• 24. Lestari NPWA, Dedy MAE, Artawan IM, Buntoro IF. Perbedaan Usia Dan Jenis Kelamin Terhadap Ketuntasan Pengobatan Tb Paru Di Puskesmas Di Kota Kupang. Cendana Med J. 2022;10(1):24-31. doi:10.35508/cmj.v10i1.6802
• 25. Greer JP, Rodgers GM, Arber DA, Means RT. Wintrobe’s Clinical Hematology. Fourteenth. (Greer JP, ed.). Wolters Kluwer; 2019. doi:10.1016/b978-012396305-5/50008-7
• 26. Kementerian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran-Tata Laksana Tuberkulosis. 1st ed.; 2020. https://tbindonesia.or.id/pustaka_tbc/pedoman-nasional-pelayanan-kedokteran-tatalaksana-tuberkulosis/
• 27. Sheetal, M. R M, Rub Patwegar A. Comparative Study of Hematological Parameters in Newly Diagnosed Tuberculosis Patient’s Pre-ATT & After Intensive Phase of ATT. IP Arch Cytol Histopathol Res. 2020;3(4):185-191. doi:10.18231/2456-9267.2018.0038
• 28. Come YFR, Buntoro IF, Setiono KW, Setianingrum ELS. Pengaruh Pemberian Terapi Obat Anti Tubekulosis Fase Intensif Terhadap Kadar Hemoglobin pada Penderita Tuberkulosis di Kota Kupang. Cendana Med J. 2023;11(1):24-32. doi:10.35508/cmj.v11i1.10515
• 29. Chhabra S, Kashyap A, Bhagat M, Mahajan R, Sethi S. Anemia and Nutritional Status in Tuberculosis Patients Abstract. Int J Appl Basic Med Res. 2021;11(4):226-230. doi:10.4103/ijabmr.ijabmr_76_21
• 30. US Army. Hematology II. 100th ed.; 2019. https://dokumen.pub/hematology-ii-md0857-100nbsped.html
• 31. Chavan SKML. Hematological Profile in Patients Suffering From Tuberculosis and Treatment Response. J Med Sci Clin Res. 2016;04(October):13189-13192. https://www.jmscr.igmpublication.org/home/index.php/archive/91-volume-4-issue-10-oct-2016/1186-hematological-profile-in-patients-suffering-from-tuberculosis-and-treatment-response
• 32. Kumar Koirala P, Khandelwal B, A. Zaman F. Study of Hematological Profile and Effect of Antitubercular Medications on the Hematological Derangements in Patients Suffering from Tuberculosis. Indian J Emerg Med. 2017;3(1):45-50. doi:10.21088/ijem.2395.311x.3117.7
• 33. Reta B, Mohammed AE, Tesfaye Kiya G, Adissu W, Shenkute TY. Impact of Anti-tuberculosis Treatment on Hematological Parameters in Newly Diagnosed Tuberculosis Patients at Jimma Town: a Longitudinal Prospective Study. Ann Med Surg. 2023;85(8):3887-3893. doi:10.1097/ms9.0000000000001084
• 34. Karwiti W, Sri Lestari W, Rezekiyah S, Kesehatan Jambi P. Perbedaan Profil Hematologi Pada Penderita Tuberkulosis Paru Yang Menjalani Pengobatan. Jambura J Heal Sci Res. 2021;3(1):126-132. doi:https://doi.org/10.35971/jjhsr.v3i1.8350
• 35. Durachim A, Astuti D. Bahan Ajar Hemostasis. In: Kementerian Kesehatan Republik Indonesia. Vol 1. ; 2018:1-237. https://medlab.id/download-ebook-hemostasis/
• 36. Chedid C, Kokhreidze E, Tukvadze N, et al. Association of Baseline White Blood Cell Counts with Tuberculosis Treatment Outcome: a Prospective Multicentered Cohort Study. Int J Infect Dis. 2020;100:199-206. doi:10.1016/j.ijid.2020.09.017
• 37. Luo M, Zou X, Zeng Q, et al. Monocyte at Diagnosis as a Prognosis Biomarker in Tuberculosis Patients with Anemia. Front Med. 2023;10(June):1-10. doi:10.3389/fmed.2023.1141949
• 38. Balepur SS, Schlossberg D. Hematologic complications of tuberculosis. Tuberc Nontuberculous Mycobact Infect. 2016;4(6):1-10. doi:10.1128/microbiolspec.TNMI7-0004-2016
• 39. Gebreweld A, Fiseha T, Kebede E, et al. Immuno-Hematological and Biochemical Changes in Patients with Tuberculosis in Dessie Comprehensive Specialized Hospital, Dessie, Ethiopia. J Blood Med. 2024;15(March):147-155. doi:10.2147/JBM.S445857
• 40. Kenzie SBM, Williams JL. Clinical Laboratory Haematology. Vol 16. Third. (Piwowar KL, ed.). Pearson Education, INc; 2015.

How to Cite This

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability